ZVRA · Zevra Therapeutics, Inc.

Adoption date of referenced 10b5-1(c) plan is: 01-08-2026.

This transaction was executed in multiple trades at prices ranging from $12.53 to $13.19. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

The first and second tranches of the restricted stock units vested and settled on June 21, 2025 and June 21, 2026, respectively, and the remaining tranche of the restricted stock units will vest and settle on the next anniversary thereafter, subject to the Reporting person's continued service through such vesting date.

The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.

This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.

This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.

This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.

This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.

This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.

This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). The option will vest and become exercisable in four equal annual installments beginning on March 1, 2027, subject to the Reporting Person's continued service on such vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

The restricted stock units will vest and settle as to one third of the restricted stock units on March 1, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.

Adoption date of referenced 10b5-1(c) plan is: 01-08-2026

The remaining shares underlying this option, which was granted on May 3, 2023, will vest one day prior to the date of the third annual meeting of the Issuer's stockholders following the day of the grant, subject to the Reporting Person's continued service as a director.

The shares underlying this option, which was granted on May 13, 2024, were fully vested.

The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, March 18, 2026.

Grant to the Reporting Person of a stock option under the Issuer's 2023 Employment Inducement Award Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. All shares underlying the option will vest in full and become exercisable immediately prior to a change of control of the Issuer. Vesting of the option will be accelerated by 12 months if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.

Adoption date of referenced 10b5-1(c) plan is: 3/21/2025.

This transaction was executed in multiple trades at prices ranging from $8.39 to $8.67. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

One third of the restricted stock units vested and settled on February 7, 2026. The remaining two thirds of the shares will vest and settle in two equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date.

Adoption date of referenced 10b5-1(c) plan is: 3/28/2025.

This transaction was executed in multiple trades at prices ranging from $8.93 to $9.52. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Adoption date of referenced 10b5-1(c) plan is: 3/27/2025.

This transaction was executed in multiple trades at prices ranging from $8.92 to $9.55. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Adoption date of referenced 10b5-1(c) plan is: 03-21-2025.

This transaction was executed in multiple trades at prices ranging from $8.94 to $9.53. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting Person's continued service through such vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Adoption date of referenced 10b5-1(c) plan is: 3/27/2025.

This transaction was executed in multiple trades at prices ranging from $8.58 to $9.04. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the shares will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date.

Adoption date of referenced 10b5-1(c) plan is: 3/28/2025.

This transaction was executed in multiple trades at prices ranging from $8.62 to $8.995. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting Person's continued service through such vesting date.

Adoption date of referenced 10b5-1(c) plan is: 3/27/2025.

This transaction was executed in multiple trades at prices ranging from $8.64 to $9.03. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Adoption date of referenced 10b5-1(c) plan is: 3/26/2025.

This transaction was executed in multiple trades at prices ranging from $8.62 to $9.04. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the shares will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.

Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.

Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.